Status:
COMPLETED
NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia
Lead Sponsor:
NanoCarrier Co., Ltd.
Collaborating Sponsors:
Orient Europharma Co., Ltd.
Conditions:
Locally Advanced and Metastatic Pancreatic Cancer
Eligibility:
All Genders
20-75 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine the recommended dose of NC-6004 according to the dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy, safety and tolerabi...
Eligibility Criteria
Inclusion
- Patients with chemo-naive, advanced pancreatic cancer
- Nonresectable, histologically or cytologically confirmed, locally advanced or metastatic pancreatic cancer
Exclusion
- Pulmonary fibrosis or interstitial pneumonia
- Marked pleural effusion or ascites above Grade 2
- Severe drug hypersensitivity
- Metastasis to the central nervous system and brain
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00910741
Start Date
May 1 2009
End Date
July 1 2013
Last Update
January 9 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Centre Singapore
Singapore, Singapore
2
Natinal Cheng Kung University Hospital
Tainan, Taiwan
3
National Taiwan University Hospital
Taipei, Taiwan
4
Taipei Veteran General Hospital
Taipei, Taiwan